Table 4.

Best tumor response per RECIST and investigator assessment through at least week 9

Response assessment, n (%)Arm A (n = 23)Arm B (n = 16)Arm C (n = 6)
Patients with measurable disease at baseline22 (96)14 (88)6 (100)
Overall response (CR + PR)4 (17)0 (0)1 (17)
    Confirmed CR0 (0)0 (0)0 (0)
    Confirmed PR 4 (17)0 (0)1 (17)
    Stable disease11 (48)9 (56)2 (33)
    Progressive disease3 (13)5 (31)2 (33)
Disease control (CR + PR + stable disease)15 (65)9 (56)3 (50)
Unevaluable patients*3 (13)1 (6)0 (0)
Patients without available response data2 (9)1 (6)1 (17)

Abbreviations: CR, complete response; PR, partial response.

  • *Patients with a response assessment before week 9, without a subsequent assessment.

  • No post baseline tumor measurements available.